Reuters logo
BRIEF-Kiadis Pharma pediatric investigation plan for ATIR101 accepted by EMA
March 28, 2017 / 5:16 AM / 8 months ago

BRIEF-Kiadis Pharma pediatric investigation plan for ATIR101 accepted by EMA

March 28 (Reuters) - Kiadis Pharma NV:

* Kiadis Pharma’s pediatric investigation plan for ATIR101 accepted by the European Medicines Agency’S Pediatric Committee

* Paves way for submission of a marketing authorization application for ATIR101 in Europe Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below